Subject(s)
Arrhythmias, Cardiac/physiopathology , Brugada Syndrome/physiopathology , Myocytes, Cardiac/metabolism , Arrhythmias, Cardiac/genetics , Brugada Syndrome/genetics , Drug Evaluation, Preclinical/methods , Drug Evaluation, Preclinical/statistics & numerical data , Gene Editing/methods , Gene Editing/statistics & numerical data , Genetic Variation/genetics , Genetic Variation/physiology , Humans , Induced Pluripotent Stem Cells/metabolismSubject(s)
Retinoblastoma/therapy , Signal Transduction/genetics , Clustered Regularly Interspaced Short Palindromic Repeats/genetics , Clustered Regularly Interspaced Short Palindromic Repeats/immunology , Gene Editing/methods , Gene Editing/statistics & numerical data , Humans , Retinoblastoma/geneticsABSTRACT
CRISPR/Cas9-mediated genome editing provides potential for therapeutic development. Efficacy and long-term safety represent major concerns that remain to be adequately addressed in preclinical studies. Here we show that CRISPR/Cas9-mediated genome editing in two distinct SOD1-amyotrophic lateral sclerosis (ALS) transgenic mouse models prevented the development of ALS-like disease and pathology. The disease-linked transgene was effectively edited, with rare off-target editing events. We observed frequent large DNA deletions, ranging from a few hundred to several thousand base pairs. We determined that these large deletions were mediated by proximate identical sequences in Alu elements. No evidence of other diseases was observed beyond 2 years of age in these genome edited mice. Our data provide preclinical evidence of the efficacy and long-term safety of the CRISPR/Cas9 therapeutic approach. Moreover, the molecular mechanism of proximate identical sequences-mediated recombination provides mechanistic information to optimize therapeutic targeting design, and to avoid or minimize unintended and potentially deleterious recombination events.
Subject(s)
Amyotrophic Lateral Sclerosis/genetics , CRISPR-Cas Systems/genetics , Gene Editing/statistics & numerical data , Superoxide Dismutase-1/genetics , Amino Acid Sequence , Animals , Disease Models, Animal , Mice , Mice, Transgenic , Superoxide Dismutase-1/chemistry , Superoxide Dismutase-1/metabolismABSTRACT
Prime editing is a novel and universal CRISPR/Cas-derived precision genome-editing technology that has been recently developed. However, low efficiency of prime editing has been shown in transgenic rice lines. We hypothesize that enhancing pegRNA expression could improve prime-editing efficiency. In this report, we describe two strategies for enhancing pegRNA expression. We construct a prime editing vector harboring two pegRNA variants for W542L and S621I double mutations in ZmALS1 and ZmALS2. Compared with previous reports in rice, we achieve much higher prime-editing efficiency in maize. Our results are inspiring and provide a direction for the optimization of plant prime editors.
Subject(s)
Acetolactate Synthase/genetics , Gene Editing/methods , Mutagenesis, Site-Directed/methods , RNA, Guide, Kinetoplastida/metabolism , Zea mays/genetics , Gene Editing/statistics & numerical data , Genetic Vectors , Plants, Genetically Modified , RNA, Guide, Kinetoplastida/genetics , Zea mays/enzymologyABSTRACT
Over the past 8 years, the widespread adoption of CRISPR-based technologies has fueled the global genome editing revolution. This platform is based on Cas molecular machines such as Cas9, Cas12, Cas13, as well as other CRISPR effector proteins that are able to alter the genome, transcriptome, and epigenome of virtually any species. Technological improvements have rendered these tools more efficient and precise, and enabled functional diversification and specialization, as recently illustrated by the rise of base editing and the quickly growing demand for prime editing constructs. Here, we discuss the continued adoption of CRISPR tools and constructs distributed by the nonprofit organization Addgene, highlight the trends in the global demand for the CRISPR toolbox, and consider the widespread attitude changes around open sharing that are having a transformative effect on speeding up science.
Subject(s)
CRISPR-Cas Systems , Gene Editing/statistics & numerical data , Clustered Regularly Interspaced Short Palindromic Repeats , Gene Editing/trendsABSTRACT
The popularity of CRISPR-based gene editing has resulted in an abundance of tools to design CRISPR-Cas9 guides. This is also driven by the fact that designing highly specific and efficient guides is a crucial, but not trivial, task in using CRISPR for gene editing. Here, we thoroughly analyse the performance of 18 design tools. They are evaluated based on runtime performance, compute requirements, and guides generated. To achieve this, we implemented a method for auditing system resources while a given tool executes, and tested each tool on datasets of increasing size, derived from the mouse genome. We found that only five tools had a computational performance that would allow them to analyse an entire genome in a reasonable time, and without exhausting computing resources. There was wide variation in the guides identified, with some tools reporting every possible guide while others filtered for predicted efficiency. Some tools also failed to exclude guides that would target multiple positions in the genome. We also considered two collections with over a thousand guides each, for which experimental data is available. There is a lot of variation in performance between the datasets, but the relative order of the tools is partially conserved. Importantly, the most striking result is a lack of consensus between the tools. Our results show that CRISPR-Cas9 guide design tools need further work in order to achieve rapid whole-genome analysis and that improvements in guide design will likely require combining multiple approaches.
Subject(s)
CRISPR-Cas Systems , Gene Editing/methods , RNA, Guide, Kinetoplastida/genetics , Animals , Benchmarking/methods , Benchmarking/statistics & numerical data , Computational Biology , Databases, Nucleic Acid/statistics & numerical data , Gene Editing/standards , Gene Editing/statistics & numerical data , Mice , SoftwareSubject(s)
Gene Editing/legislation & jurisprudence , Genetic Engineering/legislation & jurisprudence , Research/legislation & jurisprudence , China/epidemiology , Ethics, Medical , Gene Editing/statistics & numerical data , Genome, Human/genetics , Humans , Infant, Newborn , Jurisprudence , Research/economicsSubject(s)
CRISPR-Cas Systems/genetics , Gene Editing/ethics , Gene Editing/legislation & jurisprudence , Government Regulation , Patents as Topic/legislation & jurisprudence , Animals , Clinical Trials as Topic/ethics , Clinical Trials as Topic/legislation & jurisprudence , Congresses as Topic , European Union , Gene Editing/statistics & numerical data , History, 19th Century , History, 20th Century , History, 21st Century , Human Embryonic Stem Cells , Humans , Licensure , Patents as Topic/history , Patents as Topic/statistics & numerical data , Swine/genetics , United StatesABSTRACT
The amazing power of CRISPR-Cas9 gene editing tools and other related technologies has impacted all areas of biology today. It has also raised ethical concerns, particularly with regard to the possibility of generating heritable changes in the human genome - so-called germline gene editing. Although technical and safety issues suggest that this approach is far from clinical application, gene editing as a research tool is moving forward in human embryos, non-human primates and in stem cell-derived embryoids. These studies are already providing new information relevant to our understanding of normal human development, infertility, early pregnancy loss and pluripotent stem cell origins.
Subject(s)
Embryo Research/ethics , Embryonic Development/genetics , Gene Editing/ethics , Gene Editing/methods , CRISPR-Cas Systems/physiology , Embryo, Mammalian , Gene Editing/statistics & numerical data , Genome, Human , Humans , Pluripotent Stem Cells/physiologyABSTRACT
Developmental biologists have become increasingly aware that the wealth of knowledge generated through genetic studies of pre-implantation mouse development might not easily be translated to the human embryo. Comparative studies have been fueled by recent technological advances in single-cell analysis, allowing in-depth analysis of the human embryo. This field could shortly gain more momentum as novel genome editing technologies might, for the first time, also allow functional genetic studies in the human embryo. In this Spotlight article, we summarize the CRISPR-Cas9 genome editing system and discuss its potential applications and limitations in human pre-implantation embryos, and the ethical considerations thereof.